India trials of Russian Sputnik-V vaccine may end as early as March - Dr Reddy's

Drugmaker Dr Reddy's Laboratories Ltd on Wednesday rolled out a preliminary timeline for the India trials of Russia's coronavirus vaccine candidate, with the late-stage expected to be completed by as early as March 2021.

By Anuron Kumar Mitra

BENGALURU, Oct 28 (Reuters) - Drugmaker Dr Reddy's Laboratories Ltd REDY.NS on Wednesday rolled out a preliminary timeline for the India trials of Russia's coronavirus vaccine candidate, with the late-stage expected to be completed by as early as March 2021.

Chief Executive Officer Erez Israeli said enrolment to the mid-stage trial of the Sputnik-V vaccine will start in the next few weeks and the trial was likely to end by December.

"(Phase 3 trial) can be over as fast as the end of March, but it could go into April or May," Israeli said on a post-earnings press briefing, adding the timeline will depend on the Phase 2 trial results and further approvals from authorities.

With 8 million COVID-19 infections and second only to the United States, India is pinning its hopes on a vaccine to stem the spread of the pandemic.

The ongoing festive season and a state assembly election are seen by healthcare experts as adding to the challenges in containing the outbreak.

The Hyderabad-based company had received renewed approval for late-stage clinical trials in India of the Sputnik-V vaccine earlier this month, after initially signing a deal with the Russian Direct Investment Fund in September.

The company expects to enrol 100 participants for the mid-stage trial and 1,500 people for the late-stage.

Shares of the company closed 2.9% lower at 4,951 rupees in a weak Mumbai market after Dr Reddy's reported a 30.3% fall in consolidated net profit after tax from a year earlier. Net sales, however, jumped to 47.77 billion rupees from 39.98 billion rupees a year ago.

The drugmaker, which last week isolated all its data centre services as a preventive measure following a cyberattack, said it was a ransomware attack, but was yet to ascertain if any personal information was accessed.

($1 = 73.9430 Indian rupees)

FACTBOX-Worldwide coronavirus cases cross 43.88 million, death toll at 1,165,443

FACTBOX-COVID-19 vaccine frontrunners

(Reporting by Anuron Kumar Mitra in Bengaluru; Editing by Arun Koyyur)

((AnuronKumar.Mitra@thomsonreuters.com; +91 99863 58469;))

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Reuters

Reuters, the news and media division of Thomson Reuters, is the world’s largest international multimedia news provider reaching more than one billion people every day. Reuters provides trusted business, financial, national, and international news to professionals via Thomson Reuters desktops, the world's media organizations, and directly to consumers at Reuters.com and via Reuters TV.

Learn More